• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Global M&A hit hard in first quarter, with trade war and cooling growth taking toll on Asia

Share:

June 17, 2019

Global deal making activity declined in a chilly first quarter, with Asia hit especially hard by the ongoing US-China trade war, growing economic headwinds and market volatility, according to separate reports from data providers Mergermarket and Dealogic on Wednesday.

The number of mergers and acquisitions (M&A) declined by 30 per cent globally to 3,558, while the value of deals declined by 15 per cent to US$801.5 billion, data compiled by Mergermarket showed.

Large cross-border deals that propelled M&A activity in the past five years “have almost disappeared”. Only nine mega deals – defined as above US$10 billion in value – have been struck, down from 14 in the same period last year.

Cross-border M&A made up only 30.8 per cent of the global pool, lower than an average of 38-40 per cent over the past three years.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Asia, especially China, has been hit hard.
Rising protectionism, concerns about technology’s reach are politicising, delaying merger reviews, lawyers say

“The US-China trade war, domestic deleveraging efforts [in China] and increased regulatory scrutiny have made fundraising for private equity and venture capital more challenging,” Riccardo Ghia, research editor for Asia-Pacific at Mergermarket, said in the report.

M&A activity in Asia-Pacific, excluding Japan, nosedived in the first three months to 666 deals worth US$119.9 billion, their lowest value in five years. Deal value in China, which accounted for 46.6 per cent of the Asian market, almost halved.

Asia-Pacific outbound activity collapsed to levels not seen in more than six years.

Private equity firms also felt the squeeze, with buyouts plunging to 66 deals worth US$8.7 billion, their lowest value since the first quarter of 2013.

Dealogic too noted the sharp decline in M&A activity in Asia. “With rising protectionism in the region”, the value of deals plunged by 26 per cent in the first quarter to US$180.2 billion, the company said in its report.

In China, deal values and valuations have both declined. China-targeted M&A activity only reached US$77.8 billion, down by 35 per cent from the same period the previous year.

The valuation of China-targeted M&A activity has been declining for two consecutive years, with the ratio of median enterprise value and Ebitda dropping to 17.8 times in the first quarter of 2019, its lowest since 2014, when it stood at 17.7 times. The ratio compares a company’s enterprise value to its earnings before interest, taxes, depreciation and amortisation.

But there are reasons for optimism for the rest of the year.

Beranger Guille, global editorial analytics director at Mergermarket, said: “With pockets of consolidation in some particularly hot sectors, vigorous private equity activity and a healthy domestic deal flow in the US should give hope to deal makers for the rest of 2019.”

Analysts at Dealogic forecast more mega deals in the coming months, with valuations already at low levels.

M&A valuations have seen a gradual decline, with the ratio of median enterprise value and Ebitda multiples globally falling to their lowest level since 2012, at 12.01 times.

“This fall in valuation could be enough to reignite M&A fires and tempt investors into a wave of M&A deal making over the coming months,” said Dealogic.

Date: June 17, 2019

Source: South China Morning Post

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • AMAG to Acquire Ciraparantag Maker Perosphere PharmaceuticalsAMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
  • Repligen Announces Agreement to Acquire Fluid Management Innovator MetenovaRepligen Announces Agreement to Acquire Fluid Management Innovator Metenova
  • The VA, Samsung and LIVMOR Team up on Initiative to Streamline Cardiology CareThe VA, Samsung and LIVMOR Team up on Initiative to Streamline Cardiology Care
  • Hospital mergers and acquisitions: They keep happening but let’s face it, the big ones rarely workHospital mergers and acquisitions: They keep happening but let’s face it, the big ones rarely work
  • Triage Acquires Kamana HealthTriage Acquires Kamana Health
  • $2.5B Teneobio Deal Complements Amgen’s Core and Capabilities$2.5B Teneobio Deal Complements Amgen’s Core and Capabilities
  • Apple’s New Health Data Sharing Feature is Part of the Patient-Controlled Data TrendApple’s New Health Data Sharing Feature is Part of the Patient-Controlled Data Trend
  • General Catalyst’s HATCO Plans to Purchase Ohio Healthcare System Summa HealthGeneral Catalyst’s HATCO Plans to Purchase Ohio Healthcare System Summa Health

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications